DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
DarioHealth Corp.NASDAQ: DRIO
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -147.7%
Net margin was -147.7% in Q1 FY2026, down 11.1 pp from a year earlier. On a trailing-twelve-month basis it was 295.9%, up 455.7 pp year over year. Over 3 fiscal years it widened by 38.3 pp.
Context
- Net margin widened in 1 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 3 analysts of -951.3% for the fiscal year ending Dec 2026, down from -186.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -147.7%-1792.3 pp QoQ
- Last fiscal yearDec 2025
- -186.6%-28.5 pp YoY
- LTMMar 2026
- 295.9%+455.7 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -186.6%
- Year-over-year change
- -28.5pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -186.6% | -28.5pp |
| FY2024 | 2024-12-31 | -158.1% | +133.9pp |
| FY2023 | 2023-12-31 | -292.0% | -67.1pp |
| FY2022 | 2022-12-31 | -224.9% | +149.3pp |
| FY2021 | 2021-12-31 | -374.2% | — |
Net Margin vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 net margin of 295.9% is the highest of the 11 companies compared; the peer median is -35.6%.
- Its year-over-year change of +455.7 pp is the 2nd highest of 11, against a peer median of +6.0 pp.
- Over three fiscal years its change of +38.3 pp compares with a peer median of -12.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 295.9% | +455.7 pp | +38.3 pp | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | 74.1% | +45.1 pp | +31.5 pp |
| LTM Mar 2026 | -2.3% | +1.4 pp | -2.6 pp | |
| LTM Mar 2026 | -7.3% | +10.5 pp | -6.9 pp | |
| LTM Mar 2026 | -9.7% | +46.1 pp | -17.1 pp | |
| LTM Mar 2026 | -23.0% | -9.1 pp | -41.9 pp | |
| LTM Mar 2026 | -48.2% | -36.0 pp | -27.9 pp | |
| LTM Mar 2026 | -80.3% | +351.4 pp | -96.5 pp | |
| LTM Mar 2026 | -330.2% | -229.6 pp | +134.9 pp | |
| LTM Mar 2026 | -391.2% | +1097.6 pp | +2165.7 pp | |
| LTM Mar 2026 | -6450.8% | -4218.6 pp | -2288.3 pp | |
| Peer median (excluding DRIO) | -35.6% | +6.0 pp | -12.0 pp | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.51M | 27.66M | 20.35M | 27.04M | 22.36M |
| Cost of Revenue | 12.44M | 18M | 14.37M | 13.77M | 9.69M |
| Gross Profit | 8.07M | 9.66M | 5.98M | 13.27M | 12.67M |
| Gross Margin | 39.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Research & Development | 17.22M | 19.65M | 20.25M | 24.18M | 13.79M |
| Selling, General & Admin | 62.36M | 46.82M | 41.8M | 46.83M | 35.53M |
| Operating Expenses | 84.56M | 66.47M | 62.17M | 71.01M | 49.32M |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 3.56M |
| EBITDA | (70.02M) | (55.6M) | (54.38M) | (37.08M) | (34.69M) |
| EBITDA Margin | -341.3% | -201.0% | -267.2% | -137.1% | -155.2% |
| Operating Income | (76.49M) | (56.81M) | (56.19M) | (57.74M) | (36.66M) |
| Operating Margin | -372.9% | -205.4% | -276.1% | -213.6% | -163.9% |
| Interest Income | 44K | 506K | 1.87M | 1.12M | 943K |
| Interest Expense | 84K | 2.68M | 645K | 96K | 3.36M |
| Other Income / Expenses | (235K) | (5.38M) | (3.17M) | 13.15M | (4.95M) |
| Income Before Tax | (76.73M) | (62.19M) | (59.36M) | (44.6M) | (41.61M) |
| Pre-Tax Margin | -374.1% | -224.9% | -291.7% | -164.9% | -186.1% |
| Income Tax Expense | 32K | 4K | 64K | (1.85M) | 105K |
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Net Margin | -374.2% | -224.9% | -292.0% | -158.1% | -186.6% |
| EPS (Basic) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| EPS (Diluted) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| Weighted Avg Shares | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
| Weighted Avg Shares (Diluted) | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.